LGT Fund Management Co Ltd. Trims Position in Regeneron Pharmaceuticals, Inc. $REGN

LGT Fund Management Co Ltd. trimmed its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 12.6% in the second quarter, according to its most recent disclosure with the SEC. The fund owned 575 shares of the biopharmaceutical company’s stock after selling 83 shares during the period. LGT Fund Management Co Ltd.’s holdings in Regeneron Pharmaceuticals were worth $302,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Quent Capital LLC raised its holdings in shares of Regeneron Pharmaceuticals by 9.8% in the second quarter. Quent Capital LLC now owns 438 shares of the biopharmaceutical company’s stock valued at $230,000 after buying an additional 39 shares during the last quarter. 111 Capital purchased a new stake in shares of Regeneron Pharmaceuticals in the second quarter valued at about $517,000. Ameritas Advisory Services LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the second quarter valued at about $45,000. Greenwood Capital Associates LLC raised its holdings in Regeneron Pharmaceuticals by 52.3% during the second quarter. Greenwood Capital Associates LLC now owns 12,861 shares of the biopharmaceutical company’s stock worth $6,752,000 after purchasing an additional 4,419 shares in the last quarter. Finally, Ashton Thomas Securities LLC raised its holdings in Regeneron Pharmaceuticals by 6.1% during the second quarter. Ashton Thomas Securities LLC now owns 1,192 shares of the biopharmaceutical company’s stock worth $626,000 after purchasing an additional 69 shares in the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $600.00 on Friday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $1,024.36. The firm’s 50 day moving average price is $572.12 and its 200 day moving average price is $567.22. The firm has a market cap of $63.59 billion, a P/E ratio of 15.12, a price-to-earnings-growth ratio of 1.92 and a beta of 0.31. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $8.43 by $4.46. The firm had revenue of $3.68 billion for the quarter, compared to analyst estimates of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. Regeneron Pharmaceuticals’s revenue was up 3.6% compared to the same quarter last year. During the same quarter last year, the business earned $11.56 earnings per share. As a group, sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were paid a dividend of $0.88 per share. The ex-dividend date of this dividend was Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 8.87%.

Analysts Set New Price Targets

REGN has been the subject of several analyst reports. Guggenheim increased their price target on shares of Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the stock a “buy” rating in a report on Friday, August 1st. Weiss Ratings reissued a “hold (c-)” rating on shares of Regeneron Pharmaceuticals in a report on Saturday, September 27th. Raymond James Financial raised shares of Regeneron Pharmaceuticals to a “moderate buy” rating in a report on Tuesday, September 2nd. Morgan Stanley reissued an “overweight” rating and set a $761.00 price target (up from $754.00) on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Finally, Truist Financial cut their price target on shares of Regeneron Pharmaceuticals from $940.00 to $812.00 and set a “buy” rating for the company in a report on Monday, August 11th. Three research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $817.67.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.